| 摘要 |
Disclosed is the use of an inhibitor of QC selected from the group consisting of imidazole derivatives and histamine derivatives, including all pharmaceutically acceptable salts and enantiomers thereof, in combination with an inhibitor of DP IV or DP IV-like enzymes wherein the DP IV-like enzyme is selected from the group consisting of fibroblast activation protein alpha, dipeptidyl peptidase IV beta, dipeptidyl aminopeptidase-like protein, N-acetylated alpha-linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II (DP II), attractin, DP 6, DPP 8, DPP 9, DPL2 and DPP 10, and/or an aminopeptidase-inhibitor in the manufacture of a medicament for inhibiting a) the formation of a QC substrate selected from the group consisting of Abeta3-40/42, [Gln3]Abeta3-40/42, [Glu11]Abeta11-40/42, [Gln11]Abeta11-40/42 and [Gln1]CCL 2 and, subsequently, b) the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues in said QC-substrate; for the prevention or treatment of a disease selected from Alzheimer's disease and Down's syndrome. |
